Phase III Randomized Adjuvant Study of Tamoxifen Alone Versus Sequential Tamoxifen and Anastrozole in Hormone-Responsive Postmenopausal Breast Cancer Patients
Phase 3
- Conditions
- Hormone-responsive postmenopausal primary breast cancer
- Registration Number
- JPRN-C000000056
- Lead Sponsor
- -SAS BC 03 executive committee
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 2500
Inclusion Criteria
Not provided
Exclusion Criteria
(1)Invasive carcinoma of other organs (less than 5years after the last treatment) (2)Metachronous or synchronous bilateral breast cancer (3)Past deep venous embolism (4)Osteoporosis needed to be treated or past bone fracture because of osteoporosis (5)Patients judged inappropriate for this study by the physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method